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Abstract	16	
Antimicrobial	resistance	(AMR)	threats	are	typically	represented	by	bacteria	capable	of	17	
extensive	horizontal	gene	transfer	(HGT).	One	clear	exception	is	Mycobacterium	tuberculosis	18	
(Mtb).	It	is	an	obligate	human	pathogen	with	limited	genetic	diversity	and	a	low	mutation	rate	19	
which	further	lacks	any	evidence	for	HGT.	Such	features	should	in	principle	reduce	its	ability	to	20	
rapidly	evolve	AMR.	We	identify	key	features	in	its	biology	and	epidemiology	that	allows	it	to	21	
overcome	its	low	adaptive	potential.	We	focus	in	particular	on	its	innate	resistance	to	drugs,	22	
unusual	life	cycle	including	an	often	extensive	latent	phase	and	its	ability	to	shelter	from	23	
exposure	to	antimicrobial	drugs	within	cavities	it	induces	in	the	lungs.  24	
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So	Special	25	
The	rapid	increase	of	antimicrobial	resistance	(AMR;	see	Glossary)	in	bacteria	is	driven	by	the	26	
widespread	use,	abuse	and	misuse	of	antibiotics,	and	constitutes	one	of	the	most	challenging	27	
healthcare	problems	globally.	With	the	notable	exception	of	Mycobacterium	tuberculosis	(Mtb)	28	
the	agent	of	tuberculosis	(TB),	all	other	bacterial	species	listed	as	current	AMR	threats	by	the	29	
Centers	for	Disease	Control	http://www.cdc.gov/drugresistance/biggest_threats.htmltrend	30	
frequently	exchange	genetic	material	and	frequently	acquire	novel	mutations	through	gain	of	31	
new	genes	by	horizontal	gene	transfer	(HGT)	rather	than	de	novo	mutations	(Figure	1).	Mtb	has	32	
a	virtually	non-existent	accessory	genome,	meaning	that	almost	all	genes	are	common	to	all	33	
strains.	Evidence	suggests	that	there	is	little	or	no	recombination	occurring	in	the	species.	In	34	
addition	to	its	strictly	clonal	reproduction,	Mtb	is	characterized	by	a	low	mutation	rate	and	35	
limited	genetic	diversity,	which	has	led	to	it	being	considered	as	a	‘monomorphic	bacterium’	36	
[1].	Mtb	also	stands	out	from	most	other	bacteria	considered	as	AMR	threats	by	being	an	37	
obligate	pathogen.	38	
The	lack	of	HGT	combined	with	a	low	mutation	rate	makes	Mtb	an	a	priori	unlikely	foe	39	
outwitting	considerable	efforts	aiming	at	defeating	it.	Yet,	multi-drug	resistant	TB	[MDR-TB		40	
resistant	to	isoniazid	(INH)	and	rifampicin	(RIF)]	and	extensively-drug	resistant	TB	(XDR-TB;	41	
MDR-TB	with	additional	resistance	to	second-line	injectable	drugs	and	fluoroquinolones)	42	
represent	a	significant	and	growing	threat	to	global	health	accounting	for	nearly	half	a	million	43	
new	cases	and	around	200,000	deaths	in	2014	alone	44	
http://www.who.int/tb/publications/global_report/en/.	Resistance	has	also	been	shown	to	45	
emerge	essentially	immediately	after	the	introduction	of	new	drugs	and	highly	resistant	strains	46	
of	Mtb	have	been	in	circulation	for	at	least	four	decades	[2,	3].	In	this	review	we	explore	why	47	
Mtb	is	such	a	severe	public	health	problem	despite	being	an	outlier	amongst	other	AMR	48	
threats.	To	search	for	clues,	we	review	the	key	features	of	its	biology,	life	history	and	49	
epidemiology	in	the	wider	phylogenetic	context	of	the	bewildering	diversity	of	mycobacteria.		50	
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We	conclude	that	compared	to	other	bacterial	resistance	threats,	the	strict	reliance	of	Mtb	on	51	
de	novo	chromosomal	mutations	has	led	to	a	relatively	slow	rate	of	emergence	of	AMR.	52	
However,	the	proportion	of	resistant	strains	is	increasing	and	this	trend	is	proving	difficult	to	53	
contain	due	to	various	public	health	failings,	the	intrinsic	resistance	of	mycobacteria	to	a	range	54	
of	antibiotics	and	life-style	properties	such	as	the	ability	of	Mtb	to	hide	in	pulmonary	cavities	55	
and	lesions	with	limited	drug	penetrance.	56	
Roots	Bloody	Roots	57	
The	genus	Mycobacterium	contains	well	over	100	recognized	species	and	probably	an	equally	58	
large	number	of	species	yet	to	be	discovered.	The	genetic	diversity	within	described	species	59	
varies	significantly,	and	this	discrepancy	follows	a	simple	rule:	the	more	attention	a	group	of	60	
mycobacteria	has	received,	the	more	likely	it	has	been	split	into	multiple	species.	The	genus	61	
mainly	comprises	environmental	bacteria,	but	a	number	of	these	can	cause	opportunistic	62	
infections	in	humans	(Figure	2).	The	more	host-specialized	members	exhibit	a	clonal	mode	of	63	
inheritance,	but	recombination	is	frequent	in	the	genus	as	a	whole.	64	
A	comparative	analysis	including	13	mycobacterial	species	found	only	sporadic	evidence	of	65	
recombination	in	core	genes	within	Mycobacteria,	but	genome	content	analyses	suggest	that	66	
horizontal	acquisition	of	genes	is	frequent	and	played	an	important	role	in	the	evolution	of	this	67	
group	[4].	The	presence	of	numerous	genomic	islands	dispersed	across	different	mycobacterial	68	
species	is	also	suggestive	of	extensive	horizontal	gene	transfer	from	outside	the	genus	[5].	A	69	
meiosis-like	conjugational	mechanism	termed	distributed	conjugal	transfer	(DCT),	controlled	by	70	
a	chromosomally	encoded	mating-identity	locus	was	recently	discovered	in	Mycobacterium	71	
smegmatis	[6].	This	intriguing	mechanism	enables	the	transfer	of	large	unlinked	stretches	of	72	
DNA	across	entire	chromosomes.	Genomic	signatures	indicative	of	DCT	have	subsequently	been	73	
identified	in	Mycobacterium	canettii,	an	environmental	mycobacterium	closely	related	to	Mtb,	74	
suggesting	that	this	mode	of	horizontal	gene	transfer	may	play	an	important	role	in	shaping	the	75	
evolution	of	mycobacteria	[7].	76	
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Mycobacteria	are	intrinsically	resistant	to	a	number	of	antimicrobial	compounds,	an	77	
observation	that	is	often	explained	by	the	presence	of	an	impermeable	mycolic	acid-rich	cell	78	
envelope.	In	addition,	mycobacteria	are	members	of	the	order	Actinomycetales	which	also	79	
includes	Streptomyces	species,	well	known	for	their	ability	to	produce	a	wide	range	of	80	
antibiotics.	Antibiotic-producing	bacteria	must	have	defence	mechanisms	in	place	to	guard	81	
them	against	their	own	toxic	compounds.	The	inducible	whiB7	multidrug-resistance	system	82	
common	to	all	Actinomycetales	has	been	shown	to	reduce	susceptibility	to	a	wide	range	of	83	
antimicrobials,	including	macrolides,	chloramphenicol,	tetracycline	and	aminoglycosides	[8].	In	84	
Mtb,	the	regulon	includes	genes	involved	in	drug	efflux	(tap),	a	putative	macrolide	exporter	85	
(Rv1473),	the	ribosomal	methyltransferase	erm	and	the	aminoglycoside	acetyltransferase	eis	86	
[8].	87	
Mtb	and	closely	related	animal	strains,	together	with	the	leprosy	bacilli	are	unusual	insofar	they	88	
constitute	specialized	pathogens	of	humans	and	other	mammals	(Figure	2).	In	contrast	to	most	89	
other	mycobacteria,	these	bacilli	readily	transmit	between	mammalian	hosts,	a	hallmark	of	true	90	
pathogens	[9].	Despite	the	general	perception	that	leprosy	is	a	disease	of	the	past,	nearly	a	91	
quarter	million	cases	are	reported	yearly	[10].		The	ruminant-infecting	Mycobacterium	avium	92	
subsp.	paratuberculosis	also	deserves	to	be	mentioned	as	a	host-specialized	pathogen.	93	
However,	even	though	this	subspecies	can	only	grow	intracellularly,	it	can	survive	for	long	94	
periods	in	the	environment	and	transmits	via	the	faecal-oral	route	and	possibly	also	via	95	
nematodes	and	protozoa	[11].	96	
Up-	and	Down(sizing)	97	
Genome-level	comparison	of	Mtb	and	M.	marinum	revealed	that	Mtb	has	also	undergone	a	98	
process	of	genome	downsizing	on	its	path	from	an	environmental	ancestor	to	a	specialized	99	
mainly	intracellular	pathogen	[12],	but	on	a	far	more	moderate	scale	than	the	leprosy	bacilli.	100	
The	general	downsizing	has	however	also	been	accompanied	by	the	acquisition	of	a	number	of	101	
genes,	including	genes	involved	in	virulence	[12].	There	is	strong	evidence	that	recombination	102	
has	been	important	in	shaping	the	early	evolution	of	Mtb	as	it	evolved	from	an	ancestor	closely	103	
related	to	present-day	smooth	tubercle	bacilli	(STB)	[13].	A	number	of	strains	adapted	to	104	
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various	mammalian	hosts	have	evolved	from	Mtb.	Together	with	Mtb,	these	animal	strains	105	
have	been	grouped	together	in	the	so-called	Mtb	complex	(MBTC).	The	STB	M.	canettii	(not	yet	106	
accepted	as	a	valid	species	name)	is	also	generally	included	in	the	MTBC	but	evidence	suggests	107	
that	this	species	might	be	mainly	environmental	[14].	The	human	and	animal	adapted	MTBC	108	
strains	represent	a	clonal	expansion	rooted	in	the	extensively	recombining	and	genetically	109	
diverse	STB.	STB	strains	can	cause	TB	in	immunocompetent	individuals,	but	are	significantly	less	110	
virulent	than	Mtb,	and	do	not	seem	to	transmit	between	humans	[9,	15].	They	have	only	been	111	
isolated	from	sporadic	human	cases	in	East	Africa,	which	has	led	to	the	suggestions	that	this	112	
region	of	the	world	is	where	the	MTBC	originated.	The	evolutionary	history	of	the	MTBC	seems	113	
to	be	analogous	to	the	clonal	expansion	of	animal-adapted	M.	avium	strains	from	a	more	114	
diverse	environmental	group	(Box	1).	115	
No	consensus	has	been	reached	to	date	on	whether	modern	Mtb	has	retained	the	ability	to	116	
undergo	recombination	[16,	17],	but	the	sum	of	evidence	suggests	that	recombination	is	117	
exceedingly	rare.	It	is	plausible	that	some	analyses	pointing	to	relatively	high	rates	of	118	
recombination	in	Mtb	had	been	misled	by	convergent	evolution	at	a	relatively	high	number	of	119	
sites,	many	of	which	are	likely	due	to	multiple	independent	emergence	of	resistance	mutations	120	
following	exposure	to	antimicrobial	compounds	[18].	Indeed,	both	convergent	parallel	121	
evolution	and	recombination	lead	to	conflicts	between	loci	over	the	best-supported	topology	of	122	
a	phylogenetic	tree.	123	
Distance	Equals	Rate	Times	Time	124	
	125	
Comparing	mutation	rates	across	bacterial	species	is	challenging.	Fluctuation	assays	[19],	126	
despite	often	being	regarded	as	the	gold	standard,	only	allow	estimating	mutation	rates	if	all	127	
possible	mutations	yielding	resistance	to	a	given	antimicrobial	compound	are	known,	which	is	128	
generally	not	the	case.	Even	when	comparisons	are	restricted	to	experiments	using	the	same	129	
antimicrobial	compound,	estimated	mutation	rates	can	vary	due	to	variation	in	the	number	of	130	
mutations	that	can	potentially	bring	about	resistance	in	different	species.	Additionally,	the	131	
same	mutation	could	yield	variable	levels	of	resistance	in	different	species	132	
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	133	
An	alternative	approach	to	estimate	mutation	rates	relies	on	Bayesian	phylogenetic	analyses	of	134	
whole-genome	sequences	from	clinical	isolates	sampled	over	several	years	and	for	which	135	
isolation	dates	are	precisely	known.	Such	data	is	available	for	all	the	species	illustrated	in	Figure	136	
1,	and	mutation	estimates	from	independent	studies	are	highly	congruent	for	Mtb	[20-22].	In	137	
this	comparison	Mtb	has	the	lowest	rate	of	all,	with	Salmonella	enterica	next	on	the	list.	This	138	
comparison	is	by	no	means	perfect,	due	to	the	variation	in	sampling	and	methodology	between	139	
studies.	However,	the	approach	offers	the	major	advantage	that	such	mutation	rate	estimates	140	
are	scaled	over	unit	time	in	natural	conditions	(rather	than	per	generation).	As	such,	these	141	
phylogenetic	mutation	rate	estimates	capture	the	capacity	of	different	bacteria	to	adapt	to	142	
antimicrobials	in	the	wild.	The	generation	time	of	Mtb	is	indisputably	very	slow	compared	to	143	
the	vast	majority	of	clinically	important	bacteria.	As	a	result,	despite	what	seems	to	be	a	144	
relatively	unremarkable	mutation	rate	per	generation	compared	to	e.g.	Escherichia	coli	[23,	24],	145	
Mtb	evolves	at	a	very	slow	pace	compared	to	most	other	AMR	threats.	146	
	147	
An	extrapolation	of	these	short	term-term	mutation	rates	to	more	ancient	times	points	to	a	148	
fairly	recent	origin	of	Mtb	less	than	6,000	years	ago	[25,	26],	which	is	incompatible	with	149	
scenarios	of	ancient	origin	and	a	joint	colonization	of	the	globe	of	Mtb	and	anatomically	150	
modern	humans	some	40,000-70,000	years	ago	that	have	been	suggested	[27,	28].	These	age	151	
estimates	also	fit	somewhat	uncomfortably	with	direct	evidence	for	ancient	MTBC	infection	152	
from	PCR	and	the	detection	of	lipid	biomarkers	targeting	the	unusual	and	highly	stable	153	
components	of	the	cell	wall	[29].	These	include	the	detection	of	TB	in	human	remains	from	154	
Syria	some	11,000	years	ago	[30]	and	in	a	bison	from	Wyoming	dated	to	~17,000	years	ago	[31].	155	
Also	of	note	is	the	detection	of	DNA	harboring	the	Mtb-specific	TbD1-deletion	in	a	women	and	156	
child	from	Israel	some	9,000	years	ago	[32].	At	this	time,	it	seems	fair	to	accept	that	the	jury	is	157	
still	out	on	the	age	of	Mtb	and	additional	ancient	DNA	genome	sequences	will	be	required	to	158	
obtain	better	long-term	calibration	of	mutation	rates;	the	oldest	Mtb	genomes	generated	to	159	
date	being	only	about	250	years	old	[26].		160	
	161	
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Coming	Back	to	Life	162	
Mtb	has	a	very	unusual	life	cycle	with	a	long	latency	period.	About	90%	of	infected	people	163	
never	develop	active	transmissible	TB	but	stay	healthy	and	asymptomatic	[33],	possibly	because	164	
humans	have	adapted	to	control	TB	quite	efficiently	even	though	immune	activation	does	not	165	
lead	to	sterilization.	About	two	billion	people	are	estimated	to	be	latently	infected	with	TB	[34],	166	
constituting	a	massive	challenge	for	TB	eradication	efforts.	A	ten-year	follow-up	study	of	TB	167	
contacts	found	that	the	majority	of	people	that	do	develop	active	TB	do	so	within	the	first	three	168	
years	of	exposure	[33].	However,	old	age	is	also	known	to	be	a	risk	factor	for	active	TB	[35].	169	
If	Mtb	has	co-evolved	with	humans	since	the	dawn	of	our	species,	or	at	least	for	millennia,	a	170	
long	latency	period	could	be	regarded	as	an	adaptation	to	the	small	and	isolated	populations	of	171	
our	ancestors.	This	adaptation	might	have	allowed	Mtb	to	transmit	between	host	generations	172	
as	active	TB	developed	in	the	elderly	and	was	transmitted	to	the	next	generations,	without	173	
burning	through	and	killing	off	small	and	isolated	bands	of	hunter-gatherers	and	thus	174	
extinguishing	its	population	of	hosts	[36].	A	plausible	and	worrisome	scenario	is	that	modern	TB	175	
strains	are	evolving	towards	shorter	latency	periods.	There	are	now	more	than	seven	billion	176	
humans	on	the	planet	and	potential	human	TB	hosts	frequently	travel	and	migrate	between	177	
countries	and	continents.	As	such,	accelerated	progression	to	active	disease	and	hence	possible	178	
transmission,	could	be	selected	for.	In	this	context,	it	is	interesting	to	note	that	the	Beijing	TB	179	
lineage	which	has	expanded	globally	in	recent	decades	seems	to	be	associated	with	accelerated	180	
progression	to	active	TB	relative	to	other	TB	strains	and	Mycobacterium	africanum	[37].	181	
Space	Oddity	182	
Globally,	3.3	%	of	new	TB	cases	were	estimated	to	be	MDR	in	2014.	This	relatively	low	rate	183	
might	come	as	a	surprise	to	many,	and	does	conceal	significant	variation	between	and	within	184	
countries	and	regions.	In	many	western	European	countries	the	burden	is	low,	as	exemplified	185	
by	the	situation	in	the	UK,	where	1.6%	of	all	cases	were	MDR-TB	in	2013	186	
https://www.gov.uk/government/publications/tuberculosis-in-england-annual-report.	This	187	
figure	in	itself	does	not	capture	the	full	extent	of	the	problem	as	7.1%	of	strains	in	the	country	188	
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are	INH	resistant	in	the	(Figure	3),	which	is	unusually	high	for	a	western	European	country.	189	
Again,	this	figure	for	INH	resistance	does	only	very	imperfectly	capture	the	reality	on	the	190	
ground.	INH	resistant	strains	in	the	UK	are	primarily	found	in	London	and	are	patchily	191	
distributed	even	at	that	scale.	192	
TB	drug	resistance	in	the	UK	and	in	other	high	income	countries	is	a	serious	public	health	issue	193	
incurring	a	significant	financial	burden	on	public	health	services,	even	though	the	rate	of	194	
resistance	is	relatively	low	compared	to	those	found	in	some	other	resistance	threats	(Figure	3).	195	
The	extraordinarily	rapid	population-level	response	to	antibiotics	seen	for	example	in	196	
Staphylococcus	aureus	and	Enterococcus	faecium	is	striking	when	compared	to	Mtb,	and	197	
probably	partly	reflects	its	low	mutation	rate	and	lack	of	recombination	and	of	resistance-198	
determinants	on	mobile	genetic	elements	(Figure	1).	However,	Mtb	resistance	rates	in	high-199	
income	countries	are	not	representative	of	the	frequency	of	MDR/XDR-TB	strains	in	other	parts	200	
of	the	world,	and	the	burden	due	to	AMR	in	TB	resistance	is	crippling	in	some	hotspots	(Box	2	201	
and	Figure	4).	202	
Road	to	Resistance	203	
Although	intrinsically	resistant	to	many	drugs,	there	is	little	evidence	to	suggest	that	the	Mtb	204	
genome	should	be	especially	prone	to	evolving	additional	drug	resistance	(Figure	1).	In	fact,	205	
rates	of	RIF	resistance	in	M.	leprae,	which	is	not	generally	regarded	as	a	major	resistance	206	
threat,	seem	to	mirror	the	rates	found	in	Mtb.	The	inability	to	culture	M.	leprae,	and	thus	to	207	
perform	phenotypic	drug	susceptibility	testing	(DST)	complicates	analyses	of	resistance	in	this	208	
bacterium.	However,	available	data	from	India,	South-East	Asia	and	Colombia	all	found	about	209	
3%	of	all	cases	to	be	RIF	resistant	[38-40],	a	rate	that	is	similar	to	recent	estimates	of	Mtb	RIF	210	
resistance	globally	at	3.3%.	211	
The	first	outbreaks	of	MDR-TB	were	largely	restricted	to	HIV	co-infected	patients	and	often	212	
confined	to	hospitals	[41-43].	This	can	easily	be	explained	by	HIV	infection	triggering	the	213	
development	to	active	TB.	To	make	matters	worse,	HIV	and	TB	medications	have	been	shown	214	
to	negatively	interfere	with	each	other.	However,	strains	with	extensive	resistance	profiles	have	215	
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recently	been	shown	to	have	emerged		and	transmitted	well	before	the	HIV	epidemic	took	off	216	
in	the	1980s	[2,	3]	and	there	is	currently	little	evidence	to	suggest	a	causal	relationship	between	217	
HIV	co-infection	and	increased	emergence	or	circulation	of	MDR-TB	strains	[44].	218	
In	former	Soviet	Eastern	Europe	states,	the	massive	rates	of	drug	resistant	TB	have	been	219	
attributed	to	the	collapse	of	health	systems	following	the	fall	of	the	Soviet	Union	[45].	Similar	220	
forces	might	be	at	play	in	lower-middle	income	countries	such	as	India	today	where	anti-TB	221	
medication	is	available	to	most,	but	the	health	system	infrastructure	is	often	weak	and	222	
antimicrobial	stewardship	is	lacking	[46].	Another	possible	explanation	for	the	regional	223	
differences	in	resistance	burden	could	be	due	to	phenotypic	differences	between	strains.	If	the	224	
dominant	lineage	in	a	region	were	more	prone	to	develop	resistance	than	other	lineages,	this	225	
could	exacerbate	the	resistance	burden	in	the	region.	226	
The	Beijing	lineage	(Lineage	2)	is	the	dominating	lineage	in	large	parts	of	Asia	and	eastern	227	
Europe	and	is	often	associated	with	drug-resistance	[47].	Whether	members	of	the	lineage	are	228	
actually	more	prone	to	develop	resistance-conferring	mutations	as	recently	suggested	by	Ford	229	
and	colleagues	[48]	remains	unclear.	In	their	study,	Ford	et	al.	relied	heavily	on	lab	strains	[48]	230	
and	an	earlier	similar	study	with	slightly	larger	sample	size	did	not	point	to	a	higher	rate	of	231	
acquisition	of	mutations	of	Lineage	2	strains	[49].	It	is	possible	that	the	Beijing	lineage	simply	232	
happened	to	be	at	the	right	place	at	the	right	time	with	the	collapse	of	the	Soviet	Union,	233	
leading	to	the	emergence	of	resistant	strains	still	circulating	in	large	numbers	today.	The	234	
observation	that	Beijing	isolates	are	associated	with	accelerated	progression	to	active	TB	[37]	235	
could	be	part	of	the	explanation	for	the	relatively	recent	and	ongoing	global	expansion	of	the	236	
lineage.		237	
To	summarize,	worldwide	distribution	of	MDR-TB	is	extremely	heterogeneous	and	has	238	
undoubtedly	been	shaped	by	past	failings	in	public	health	infrastructure	in	various	parts	of	the	239	
world.	This	heterogeneity	might	have	been	further	exacerbated	by	an	intrinsic	propensity	of	240	
certain	lineages	to	acquire	resistance	more	readily.	However,	lineage-specific	factors	are	241	
difficult	to	quantify	because	Mtb	lineages	are	themselves	patchily	distributed.	242	
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	243	
My	Body	Is	a	Cage	244	
The	first	clinical	stage	of	TB	infection	is	termed	primary	TB	and	typically	involves	the	production	245	
and	spread	of	granulomas	systemically	and	to	regional	lymph	nodes	[50].	Within	a	few	weeks,	246	
immunity	develops	and	the	infection	regresses,	but	is	not	sterilized	[50].TB	is	generally	more	247	
virulent	in	animals	than	in	humans,	and	common	animal	models	such	as	mice,	guinea	pigs,	248	
rabbits	and	monkeys	all	develop	aggressive	primary	TB	that	is	not	transmissible	and	often	249	
results	in	death	[51].	Humans	are	special	in	that	primary	TB	is	generally	not	associated	with	250	
serious	illness.	In	humans	however,	Mtb	enters	a	latent	stage	following	regression	of	the	251	
primary	infection.	Upon	re-activation	of	the	dormant	organisms	or	reinfection	with	new	252	
organisms	from	the	environment,	softened	and	fragmented	lung	tissue	is	coughed	up	leaving	253	
cavities	that	harbor	small	numbers	of	bacilli.	This	early	stage	of	cavity	formation	can	erode	254	
arteries	to	produce	heavy	bleeding,	a	classical	sign	of	TB	[50].	Upon	maturation,	cavities	255	
develop	a	thin	fibrous	wall.		The	inner	surface	is	covered	with	fluid	caseum	with	no	viable	cells.	256	
Mtb	grows	extracellularly	on	the	surface	of	such	cavities	as	a	pellicle	(biofilm)	[52].	Mtb	can	257	
grow	in	massive	numbers	on	the	surface	of	cavities	where	it	can	be	coughed	into	the	258	
environment	while	the	host	remains	in	health	except	for	the	coughing	[50].	This	form	of	clinical	259	
TB	is	obviously	extremely	transmissible	as	billions	of	bacteria	can	be	produced	each	day	[53].	260	
In	addition	to	the	role	of	cavities	in	the	transmission	of	TB,	they	constitute	a	significant	261	
complication	for	successful	antimicrobial	therapy	as	different	drugs	penetrate	cavities	with	262	
varying	efficiency:	The	fluoroquinolone	moxifloxacin	seem	to	penetrate	well,	whereas	the	first-263	
line	drugs	INH,	RIF	and	pyrazinamide	(PZA)	are	less	efficient	[54].	The	more	experimental	drug	264	
linezolid	has	been	shown	to	be	effective	against	cavitary	TB,	albeit	often	with	quite	serious	side-265	
effects	[55].	Mathematical	modelling	has	revealed	that	using	drugs	with	different	penetration	266	
profiles	leads	to	spatial	monotherapy	and	rapid	evolution	of	multidrug	resistance	[56].	It	is	no	267	
surprise	then,	that	cavitary	TB	is	associated	with	treatment	failure	[57]	and	is	a	major	risk	factor	268	
for	acquired	resistance	to	second-line	drugs	[58,	59].	In	fact,	a	recent	study	from	Georgia	found	269	
additional	resistance	to	emerge	in	58%	of	cavitary	MDR-TB	cases	treated	with	second	line	270	
	
	
12	
	
drugs,	but	in	‘only’	16%	of	such	patients	not	presenting	with	cavities	[58].	Efforts	to	optimize	271	
regimens	for	progressed	cavitary	TB	minimizing	resistance	development	are	warranted.	272	
The	emergence	of	drug	resistant	TB	is	most	often	attributed	to	poor	patient	adherence	to	drug	273	
treatment	schemes,	a	problem	that	is	ameliorated	by	directly	observed	treatment	(DOT).	274	
Patients	are	typically	enrolled	on	anti-TB	therapy	for	6	to	24	months,	depending	on	response	275	
and	the	resistance	phenotype	of	the	infection.	In	light	of	this	one	cannot	expect	the	problem	of	276	
imperfect	patient	compliance	to	go	away	anytime	soon.	Yet,	based	on	a	hollow-fiber	model,	277	
pharmacokinetic	variability	alone	was	estimated	to	result	in	acquired	multidrug-resistance	in	278	
about	1%	of	patients,	irrespective	of	adherence	[60].	Many	bacteria	exhibit	increased	drug	279	
tolerance	when	growing	in	biofilms	and	this	phenomenon	has	also	been	observed	in	Mtb.	Bacilli	280	
in	cavities	are	also	separated	from	the	host’s	immune	defenses	by	the	wall	of	the	cavity	that	281	
prevents	penetration	of	viable	cells.	When	allowed	to	form	biofilms	in	vitro,	a	small	but	possibly	282	
clinically	important	subpopulation	emerges,	which	is	able	to	tolerate	very	high	doses	of	283	
antimicrobials	[61].	Mtb	biofilm	formation	was	recently	shown	to	depend	on	keto-mycolic	acids	284	
and	when	co-cultured	with	a	wild-type	strain,	even	drug	sensitive	biofilm-defective	mutants	285	
were	found	to	become	drug	tolerant	[62].	The	biological	relevance	of	biofilm	formation	within	286	
patients	remains	to	be	determined,	but	the	biofilm-like	growth	of	Mtb	within	and	on	the	287	
surface	of	cavities	[52]	suggest	that	this	growth	mode	could	be	clinically	very	important.	288	
Chemical	Warfare	289	
Recent	studies	utilizing	deep-sequencing	of	patient	isolates	have	revealed	a	surprising	degree	290	
of	Mtb	genetic	diversity	within	patients	[63-67].	Resistance	mutations	have	been	found	to	291	
emerge	multiple	times	within	a	single	patient,	generally	followed	by	selective	sweeps	resulting	292	
in	one	clone	replacing	the	whole	within-host	population	[63,	66,	67].	Large	Mtb	population	sizes	293	
and	significant	genetic	diversity	upon	diagnosis	surely	play	important	roles	in	the	emergence	of	294	
resistance,	as	a	diverse	population	is	more	likely	to	encompass	mutants	with	decreased	295	
susceptibility	to	anti-TB	therapeutic	drugs.	The	importance	of	within-host	Mtb	population	size	296	
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and	genetic	diversity	in	resistance	development	is	a	research	avenue	that	deserves	further	297	
attention.	298	
Even	more	worrisome	than	resistance	evolving	in	individual	patients	is	the	transmission	of	299	
resistant	strains	with	little	or	no	apparent	fitness	cost	to	the	bacterium.	The	overall	robustness	300	
of	Mtb	when	challenged	with	antimicrobials	led	to	standardized	drug	treatment	schemes	301	
including	a	cocktail	of	four	drugs.	Unfortunately,	these	schemes	are	not	always	paired	with	302	
robust	drug-susceptibility	testing.	It	has	been	argued	that	standardized	treatment	schemes	for	303	
susceptible	and	MDR-TB	in	the	absence	of	phenotypic	resistance	testing	has	been	a	direct	304	
driver	of	the	evolution	of	XDR-TB	in	South	Africa	[68].	It	is	well	documented	that	the	most	305	
commonly	transmitted	RIF-resistance	mutation	rpoB	S450L	in	combination	with	secondary	306	
compensatory	mutations	in	polymerase	subunits	is	associated	with	little	or	no	fitness	cost	[69,	307	
70]	whereas	the	picture	is	less	clear	for	INH-resistance.	It	has	however	been	shown	that	the	308	
most	common	INH-resistance	mutation,	namely	katG	S315T	retains	residual	catalase-309	
peroxidase	activity,	is	virulent	in	mice,	and	importantly,	transmits	well	between	people	[71,	72].	310	
Recent	studies	have	documented	that	MDR-TB	strains	have	been	in	circulation	for	decades	[2,	311	
3].	The	four-drug	anti-TB	regimen	currently	in	use	includes	drugs	that	have	all	been	used	312	
continuously	against	TB	for	40-60	years.	It	may	thus	come	as	no	surprise	that	this	has	selected	313	
for	highly	transmissible	MDR-TB	strains,	and	we	might	perhaps	consider	ourselves	lucky	that	314	
the	problem	is	not	yet	worse	than	it	is.	315	
Concluding	Remarks:	Know	Your	Enemy	316	
Essentially	irrespectively	of	the	feature	under	scrutiny,	Mtb	stands	out	from	all	other	bacteria	317	
considered	as	AMR	threats.	Some	of	these	peculiarities	should	constitute	major	chinks	in	its	318	
armor	making	it	a	tractable	target	for	a	rare	success	in	stemming	the	rise	of	AMRs.	In	particular,	319	
Mtb	has	a	low	mutation	rate	and	limited	genetic	diversity,	lacks	any	mechanism	for	extensive	320	
HGT	and	does	not	benefit	from	any	hiding	place	outside	its	human	host,	such	as	an	321	
environmental	or	zoonotic	reservoir.	It	remains	to	be	defined	what	exact	form	a	determined	322	
assault	against	AMR-TB	(and	TB	more	generally)	should	take.	However,	it	is	clear	that	any	323	
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successful	public	health	strategy	will	have	to	be	informed	by	robust	fundamental	scientific	324	
evidence	and	be	multipronged	to	be	successful.	We	have	learned	a	lot	about	Mtb	and	TB,	in	325	
particular	since	the	advent	of	fast	and	affordable	sequencing	technologies.	However,	it	would	326	
be	foolish	to	assume	that	the	current	knowledge	is	sufficient	to	vanquish	Mtb	(see	Outstanding	327	
Questions),	as	it	remains	a	deadly	and	surprisingly	adaptable	foe	despite	its	apparent	inherent	328	
weaknesses.	329	
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Figures	539	
	540	
	541	
Figure	1.	Basic	Genomic	Features	of	the	Main	Bacterial	Resistance	Threats.	The	core	genome	542	
proportion	indicates	the	proportion	of	typical	individual	genomes	that	are	common	to	all	543	
members	of	the	species.	Mutation	rates	are	based	on	whole-genome	phylogenetic	analyses	of	544	
clinical	isolates.	The	presence	of	plasmid-	or	phage-mediated	resistance	is	indicated	in	the	545	
figure.	In	this	figure	we	considered	M.	tuberculosis	to	have	entirely	lost	the	ability	to	recombine	546	
(see	main	text	for	a	brief	discussion	on	possible	recombination	in	M.	tuberculosis).	547	
Acinetobacter	baumanni	was	not	included	in	the	figure	as	we	could	not	find	relevant	estimates	548	
for	mutation	rates	and	recombination/mutation	ratio. 549	
	
	
21	
	
	550	
Figure	2.	History	and	Host	Range	of	Important	Mycobacterial	Pathogens.	The	figure	includes	551	
the	 most	 important	 pathogens	 in	 the	 genus	 Mycobacterium.	 SGM	 =	 slow-growing	552	
mycobacteria;	 RGM	 =	 rapid-growing	 mycobacteria.	M.	 tuberculosis	 and	 related	 species	 are	553	
descendants	from	a	hypothetical	environmental	ancestral	species	termed	M.	prototuberculosis,	554	
whereas	M.	ulcerans	evolved	from	a	M.	marinum-like	ancestor.	The	acquisition	of	the	pMUM	555	
mega-plasmid	 containing	 genes	 required	 for	 the	 synthesis	 of	mycolactone	was	 central	 in	 the	556	
evolution	 of	 this	 pathogen.	 Pictograms	 indicate	 host	 range,	 whereas	 the	 presence	 of	 a	 tree	557	
specifically	 indicates	 that	 the	 species	 is	 environmental.	 M.	 avium	 and	 M.	 abscessus	 are	558	
separated	into	subspecies. 559	
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	560	
	561	
Figure	3.	Population-level	Response	to	Antimicrobials	of	Selected	Pathogens,	United	Kingdom	562	
From	left:	Percentage	of	Mtb	clinical	isolates	resistant	to	isoniazid	(INH-res	Mtb)	(From	1960-563	
1983	only	new	cases	[73,	74],	from	1988-2013	all	cases	[75,	76];	Invasive	E.	faecium	isolates	564	
resistant	to	vancomycin	(VAN-res	Efa)		[77];	Invasive	S.	aureus	isolates	resistant	to	methicillin	565	
(MET-res	Sau). [78,	79].	For	E.	faecium	and	S.	aureus,	data	for	the	years	2001-2013	was	566	
retrieved	from	http://www.bsacsurv.org/.	Shaded	areas	correspond	to	95%	confidence	567	
intervals	based	on	local	regression.	Mtb	data	from	England	and	Wales	1960-1999;	England,	568	
Wales	and	Northern	Ireland	2000-2005;	UK	2005-2013.	E.	faecium	data	from	England	and	569	
Wales	1990-1998;	UK	and	Ireland	2001-2013.	S.	aureus	data	from	England	and	Wales	1989-570	
1996;	UK	and	Ireland	from	2001-2013.	571	
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 572	
Figure	4.	Hotspots	of	MDR-TB.	Data	on	MDR-TB	incidence	was	collected	from	[80]	(Belarus),	573	
[81]	(Mumbai)	and	[82]	(KwaZulu-Natal).	Note	that	the	MDR-TB	frequencies	reported	here	for	574	
Mumbai	are	significantly	higher	than	those	reported	nation-wide	from	the	World	Health	575	
Organization.	The	reported	MDR-TB	incidence	in	KwaZulu-Natal	represents	RIF-resistant	576	
isolates	as	identified	by	TB	Xpert	[83].	 	577	
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Text	Boxes	578	
Box	1	You	all	look	the	same	to	me 579	
M.	abscessus	is	a	rapidly	growing	environmental	species	but	also	a	relatively	common	source	of	580	
soft	tissue	infections,	disseminated	infections	in	immunocompromised	individuals	and	581	
pulmonary	infection	in	cystic	fibrosis	patients.	Treating	M.	abscessus	infections	with	582	
antimicrobials	is	challenging,	as	the	group	is	intrinsically	resistant	to	most	available	drugs	[84].	583	
The	species	harbors	three	subspecies,	namely	abscessus,	bolettii	and	masilliense.	The	macrolide	584	
clarithromycin	has	been	used	frequently	to	treat	infections,	but	the	relatively	recent	discovery	585	
that	nearly	all	abscessus	and	bolettii	strains,	but	not	masilliense,	can	induce	resistance	to	the	586	
drug	by	activation	of	the	erm(41)	gene	[85],	encoding	a	ribosome	methylase	[86],	highlights	587	
critical	differences	within	this	species	complex	and	the	need	for	improved	taxonomic	588	
assignment	tools	for	effective	treatment.	589	
M.	avium	is	a	species	consisting	of	four	main	subspecies	ranging	from	environmental	to	more	590	
specialized	pathogens.	M.	avium	subsp.	homoinissuis,	an	environmental	species	causing	591	
opportunistic	infection	in	immune-compromised	people,	is	a	diverse	group	undergoing	592	
frequent	recombination	events.	In	contrast,	the	subspecies	silvaticum,	avium	and	593	
paratuberculosis	represent	clonal	lineages	radiating	out	of	the	hominisuis	group	that	have	594	
adapted	to	various	animal	hosts	[87](Fig.	2).	595	
M.	ulcerans	falls	somewhere	in	the	middle	of	the	spectrum	between	environmental	and	host-596	
specialized	mycobacteria.	The	bacterium	can	be	considered	as	a	semi-specialized	pathogen	597	
mainly	due	to	the	acquisition	of	the	pMUM	plasmid	by	a	M.	marinum-like	ancestor	[88].	The	598	
plasmid	encodes	the	genes	necessary	for	the	synthesis	of	mycolactone,	a	polyketide-derived	599	
macrolide	that	serves	both	as	a	toxin,	triggering	tissue	damage,	and	an	immunomodulatory	600	
compound	inhibiting	the	host	immune	response.	Analogous	to	Mtb	and	the	leprosy	bacilli,	M.	601	
ulcerans	has	undergone	significant	gene	loss	and	contains	771	pseudogenes,	in	stark	contrast	to	602	
M.	marinum,	where	only	65	inactivated	genes	have	been	identified	[88].	This	pseudogenization	603	
seems	to	have	been	partially	driven	by	the	expansion	of	insertion	sequence	IS2404	that	was	604	
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acquired	after	the	split	between	M.	marinum	and	M.	ulcerans.	Insertion	sequences	seem	to	605	
have	played	important	roles	also	in	the	host-adaption	of	other	pathogenic	mycobacteria.	M.	606	
ulcerans	has	been	identified	in	a	wide	range	of	environments,	including	soil,	water,	frogs,	fish,	607	
mosquitos,	water	bugs	and	mammals.	However,	the	finding	that	mycolactone	specifically	608	
inhibits	T-cell	controlling	mammalian	microRNAs	[89]	combined	with	a	very	close	genetic	609	
relationship	between	M.	ulcerans	isolates	in	humans	and	opossums	in	southwest	Australia	[90]	610	
do	suggest	that	the	bacterium	has	evolved	to	accommodate	a	mammalian	niche.	611	
	 	612	
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Box	2	Terrible	Places	(for	MDR-TB)	613	
In	India,	4.3	%	of	notified	TB	cases	were	estimated	to	be	MDR-TB	in	2013,	but	within	the	614	
country	there	are	significant	regional	differences	in	resistance	burden.	A	survey	of	four	615	
municipal	wards	in	Mumbai	revealed	rates	of	MDR-TB	close	to	30%	in	the	years	2004-2007	[81]	616	
(Figure	4)	and	subsequent	studies	have	confirmed	very	high	rates	of	drug	resistance	[91,	92].	A	617	
significant	proportion	of	the	MDR-isolates	are	resistant	to	additional	drugs,	exemplified	by	a	618	
study	from	2013	that	found	10.6	%	of	all	MDR-TB	isolates	to	qualify	for	XDR-TB	status	[91].	619	
Results	from	first-line	diagnostics	reported	annually	in	South	Africa	found	6.6	%	of	all	TB	cases	620	
in	South	Africa	to	be	RIF	resistant	in	2013/2014	[83].	However,	in	the	province	of	KwaZulu-Natal	621	
which	is	home	to	30%	of	all	TB	cases	in	the	country,	and	the	region	with	the	highest	incidence	622	
of	MDR-TB	in	the	world,	8.9%	of	TB	cases	were	RIF	resistant	in	the	same	period.	RIF-resistance	623	
is	often	used	as	a	proxy	for	MDR,	an	assumption	that	is	correct	in	more	than	90%	of	the	cases	in	624	
KwaZulu-Natal	[82],	but	does	not	hold	for	instance	in	the	UK.	These	numbers	suggest	that	the	625	
WHO	estimates	from	2013	of	rates	of	around	2.1	%	of	MDR-TB	are	overly	optimistic.	626	
A	study	conducted	in	Minsk	(Belarus)	in	2009-2010	revealing	that	almost	half	of	all	TB	cases	627	
were	MDR	raised	a	few	eyebrows	[93].	However,	these	figures	were	confirmed	by	a	follow-up	628	
country-wide	study	one	year	later	that	confirmed	that	45.5%	of	all	isolates	in	Belarus	are	629	
indeed	MDR-TB.	Possibly,	even	more	shocking	was	the	observation	that	among	MDR-TB	630	
isolates,	11.9%	were	XDR	[80].	 631	
	 	632	
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Glossary	Box	633	
Ancient	DNA	(aDNA):	is	DNA	isolated	from	any	ancient	specimen.	It	is	generally	loosely	used	to	634	
describe	any	DNA	recovered	from	biological	material	that	has	not	been	preserved	specifically	635	
for	later	DNA	sequencing.	Examples	include	DNA	recovered	from	archaeological	and	historical	636	
skeletal	material,	mummified	tissues	and	archival	collections	of	non-frozen	specimens.	637	
Antimicrobial	resistance	(AMR):	is	resistance	of	a	microorganism	to	an	antimicrobial	638	
compound	to	which	it	was	originally	sensitive.	Resistant	organisms	(bacteria,	fungi,	viruses	and	639	
some	parasites)	are	able	to	withstand	exposure	to	antimicrobial	drugs,	so	that	standard	640	
treatments	become	ineffective	and	infections	persist	increasing	the	risk	of	transmission	to	641	
other	hosts.	The	evolution	of	resistant	strains	is	a	natural	phenomenon	generally	induced	by	642	
exposure	to	antimicrobial	drugs.	643	
Directly	observed	therapy	(DOT):	case	management	that	helps	to	ensure	that	patients	adhere	644	
to	treatment.	DOT	is	considered	the	most	effective	strategy	for	making	sure	patients	take	their	645	
medicines.	646	
Drug	susceptibility	testing	(DST):	the	various	procedures	to	find	out	which	drugs	a	bacterial	647	
strain	is	resistant	to.	This	represents	an	essential	step	for	rapid	identification	of	resistant	strains	648	
so	that	patients	carrying	such	strain	can	be	put	on	adequate	drug	treatment	as	soon	as	649	
possible.	650	
Isoniazid	(INH):	an	antibiotic	used	as	a	first-line	agent	together	with	rifampicin	(RIF)	in	the	651	
prevention	and	treatment	of	both	latent	and	active	TB.	652	
Multi-drug-resistant	tuberculosis	(MDR-TB):	defined	as	a	form	of	TB	infection	caused	by	653	
bacteria	that	are	resistant	to	treatment	with	at	least	two	of	the	first-line	anti-TB	drugs,	isoniazid	654	
(INH)	and	rifampicin	(RIF).	655	
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Mycobacterium	tuberculosis	complex	(MTBC):	a	group	of	closely	related	strains	and	species	656	
including	pathogens	of	humans	and	animals	as	well	as	the	highly	diverse	probably	657	
environmental	Mycobacterium	canettii.	658	
Rifampicin	(RIF):	an	antibiotic	used	to	treat	a	number	of	bacterial	infections.	It	constitutes	one	659	
of	the	two	first-line	agents	together	with	isoniazid	(INH).	It	is	on	the	World	Health	660	
Organization's	List	of	Essential	Medicines,	the	most	important	drugs	needed	in	a	functional	661	
basic	public	health	system.	662	
Smooth	tubercle	bacilli	(STB):	a	group	of	mycobacteria	found	in	Eastern	Sub-Saharan	Africa	and	663	
are	considered	as	the	putative	ancestors	of	Mtb.	They	include	in	particular	the	species	M.	664	
canettii	that	can	cause	TB	but	does	not	seem	to	transmit	directly	between	human	hosts.	665	
Tuberculosis	(TB):	a	bacterial	infection	caused	by	some	species	in	the	genus	Mycobacterium,	666	
with	the	main	agent	being	M.	tuberculosis.	The	infection	generally	resides	in	the	lungs	but	can	667	
spread	through	the	lymph	nodes	and	bloodstream	to	any	organ.	Most	people	who	are	infected	668	
by	Mtb	remain	healthy	and	asymptomatic	and	do	not	transmit	the	bacterium	to	others.	669	
Extensively	drug-resistant	TB	(XDR-TB):	a	type	of	multidrug-resistant	tuberculosis	(MDR-TB)	670	
that	is	resistant	to	isoniazid	and	rifampin,	plus	any	fluoroquinolone	and	at	least	one	of	the	three	671	
injectable	second-line	drugs	(i.e.,	amikacin,	kanamycin,	or	capreomycin). 672	
